ArticleAnnals of biomedical engineering2026
Bio-inks with PRF Increase Human Osteosarcoma Cell Line (SaOS-2) Viability in Extrusion-Based 3D-Bioprinted Constructs.
Article in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeThe growing demand for functional tissues and organs has driven advances in tissue engineering, particularly through 3D bioprinting. However, the mechanical stress associated with extrusion can compromise cell viability, limiting its clinical applicability. This study aimed to evaluate the viability of mature osteoblast-like cells (SaOS-2) in alginate-based bioinks supplemented with different platelet concentrates, platelet-rich plasma (PRP), platelet-poor plasma (PPP), platelet-rich fibrin (PRF), and injectable PRF (iPRF) to identify formulations that enhance cell survival post-printing.
methodsBioinks composed of alginate and varying concentrations (10% and 20%) of platelet concentrates were prepared and characterized rheologically. SaOS-2 cells were embedded in the bioinks and printed using extrusion-based 3D bioprinting. Printed scaffolds were analyzed for cell viability using the LIVE/DEAD assay and confocal microscopy at 24, 48, and 72 hours post-printing.
resultsRheological analysis confirmed the printability of constructs containing 10% PPP, 10% PRF, and 20% PRF. Cell viability exceeded 58% at 24 hours and 80% at 48 hours across all tested bioinks. Notably, PRF-containing constructs demonstrated viability recovery up to 86% at 72 hours, suggesting a protective and regenerative role.
conclusionPRF-enriched bioinks significantly improve cell viability after extrusion and enhance the physical integrity of bioprinted scaffolds. These results support the potential of PRF-based bioinks as promising candidates for clinically relevant bone tissue engineering applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.